{"title":"Ricci-GraphDTA: A graph neural network integrating discrete Ricci curvature for drug–target affinity prediction","authors":"Xiangxiang Zheng , Zhongrong Zhang , Xiaona Zhang , Nengzhi Jin , Yunyun Zhang","doi":"10.1016/j.jmgm.2025.109170","DOIUrl":null,"url":null,"abstract":"<div><div>Drug–target affinity (DTA) prediction facilitates accelerated drug screening and reduces development costs. To enhance prediction performance and generalization capability, this paper proposes a DTA prediction model based on discrete curvature, named Ricci-GraphDTA, which integrates molecular graph and protein sequence modeling for efficient and accurate DTA prediction. The model consists of three parts: feature encoding, input representation learning, and affinity prediction. In the feature encoding stage, drug molecules are modeled as graphs, where Forman curvature is introduced to adjust the weights of neighbor information aggregation. A GIN residual network is then used to capture the local geometric and topological features of molecules. Protein sequences are modeled using BiLSTM to extract global dependency features, enhanced by an attention mechanism to capture long-range dependencies and key residue interactions—overcoming the limitations of traditional CNNs in handling long-range dependencies. In the input representation learning stage, the high-level representations of drugs and proteins are concatenated and passed through multiple nonlinear transformations to extract cross-modal interaction features, which are then used for affinity prediction. Experimental results demonstrate that Ricci-GraphDTA exhibits significant performance across various evaluation metrics on the Davis and KIBA datasets. Further cold-start experiments demonstrate the strong generalization ability of Ricci-GraphDTA in scenarios involving unseen drugs or targets, highlighting its potential in real-world drug discovery applications. On average, it achieves a 22.5% reduction in MSE across three cold-start tasks, with over 42% reduction in the dual cold-start setting, showcasing excellent structural modeling capability and robustness.</div></div>","PeriodicalId":16361,"journal":{"name":"Journal of molecular graphics & modelling","volume":"142 ","pages":"Article 109170"},"PeriodicalIF":3.0000,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of molecular graphics & modelling","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S109332632500230X","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
Abstract
Drug–target affinity (DTA) prediction facilitates accelerated drug screening and reduces development costs. To enhance prediction performance and generalization capability, this paper proposes a DTA prediction model based on discrete curvature, named Ricci-GraphDTA, which integrates molecular graph and protein sequence modeling for efficient and accurate DTA prediction. The model consists of three parts: feature encoding, input representation learning, and affinity prediction. In the feature encoding stage, drug molecules are modeled as graphs, where Forman curvature is introduced to adjust the weights of neighbor information aggregation. A GIN residual network is then used to capture the local geometric and topological features of molecules. Protein sequences are modeled using BiLSTM to extract global dependency features, enhanced by an attention mechanism to capture long-range dependencies and key residue interactions—overcoming the limitations of traditional CNNs in handling long-range dependencies. In the input representation learning stage, the high-level representations of drugs and proteins are concatenated and passed through multiple nonlinear transformations to extract cross-modal interaction features, which are then used for affinity prediction. Experimental results demonstrate that Ricci-GraphDTA exhibits significant performance across various evaluation metrics on the Davis and KIBA datasets. Further cold-start experiments demonstrate the strong generalization ability of Ricci-GraphDTA in scenarios involving unseen drugs or targets, highlighting its potential in real-world drug discovery applications. On average, it achieves a 22.5% reduction in MSE across three cold-start tasks, with over 42% reduction in the dual cold-start setting, showcasing excellent structural modeling capability and robustness.
期刊介绍:
The Journal of Molecular Graphics and Modelling is devoted to the publication of papers on the uses of computers in theoretical investigations of molecular structure, function, interaction, and design. The scope of the journal includes all aspects of molecular modeling and computational chemistry, including, for instance, the study of molecular shape and properties, molecular simulations, protein and polymer engineering, drug design, materials design, structure-activity and structure-property relationships, database mining, and compound library design.
As a primary research journal, JMGM seeks to bring new knowledge to the attention of our readers. As such, submissions to the journal need to not only report results, but must draw conclusions and explore implications of the work presented. Authors are strongly encouraged to bear this in mind when preparing manuscripts. Routine applications of standard modelling approaches, providing only very limited new scientific insight, will not meet our criteria for publication. Reproducibility of reported calculations is an important issue. Wherever possible, we urge authors to enhance their papers with Supplementary Data, for example, in QSAR studies machine-readable versions of molecular datasets or in the development of new force-field parameters versions of the topology and force field parameter files. Routine applications of existing methods that do not lead to genuinely new insight will not be considered.